Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1332

Farletuzumab

Home » Farletuzumab

Background of Farletuzumab

Farletuzumab, also known as MORAb-003 , constitutes a humanized monoclonal antibody with an affinity for the folate receptor a. In laboratory settings, farletuzumab exhibits the capacity to impede folate receptor a-dependent cell proliferation while instigating tumor cell destruction through complement-dependent cytotoxicity and antibody-dependent cytotoxicity mechanisms. Further bolstering its therapeutic potential, evidence suggests that farletuzumab restrains tumor growth by hindering lyn kinase phosphorylation mediated by folate receptor a. Notably, comprehensive immunohistochemical analyses conducted on human and primate tissues affirm the specificity of farletuzumab's binding to its target, displaying an absence of cross-reactivity with normal tissues.

Specifications

Catalog Number:
KB-1332
Antibody Name:
Farletuzumab
Isotype:
Human IgG1,kappa
FC Muations:
Wild Type
Target:
FOLR1
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Ebel W, Routhier EL, Foley B, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-α. Cancer Immun 2007;7:6.
  2. Kelemen LE. The role of folate receptor α in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 2006;119:243–50.